ASCO 2022 Resources - Biognosys

ASCO 2022 Resources

Research Services Portfolio – Transformative Insights from Discovery to Clinic

This comprehensive brochure provides an overview of our services offering.

TrueDiscovery™ Brochure – Unbiased Biological Insights from Tissue and Biofluids

The brochure provides you with an overview of the key features and benefits of our next-generation TrueDiscovery™ platform. In addition, it elaborates on our deep and reproducible proteome, phospho- and immune-proteome quantification and analysis. Finally, it digs into how we identify the most promising and actionable biomarkers for research and clinical decision-making.

TrueTarget™ Brochure – Novel Drug Target Identification and Validation

Learn more about Biognosys’ proprietary TrueTarget™ platform in our latest brochure. This resource elaborates on how TrueTarget™ identifies the most promising and actionable drug targets to support your research.

TrueSignature™ Brochure – Custom Panels for Absolute Protein Quantification

The brochure provides you with an overview of the key features and benefits of our next-generation TrueSignature™ platform. In addition, it elaborates on the specificities of our customizable panels for clinical and pharmacodynamics studies.

White Paper – How To Accelerate And De-Risk Drug Development In Oncology

In this white paper, you can learn about the key reasons why oncology drug development fails and how Biognosys’ proteomics platforms and applications can support your oncology research pipeline by:

• Understanding the right biology
• Hitting the right target
• Developing the right biomarkers

White Paper – Accelerating Biomarker Discovery With Large-Scale Plasma Proteomics

Our White Paper explains how advances in mass spectrometry can now unlock the potential of the plasma proteome, uncovering actionable insights that are essential for biomarker discovery and targeted drug development.

Case Study – Multi-omics Biomarker Analysis Identifies Unique Immune Activation Signature in Pancreatic Cancer

We describe a first-of-its-kind study using multi-omics biomarker approaches to demonstrate pharmacodynamic effects and immune modulation in pancreatic cancer. Biognosys’ proprietary platform for unbiased proteomics, TrueDiscovery™, allowed the identification of pharmacodynamic markers and elucidated the mechanism of action of therapies under clinical investigation.

Case Study – Biomarker Candidates for Tumors Identified from Deep‐profiled Plasma Stem Predominantly from the Low Abundant Area

The case study provides you with an overview of the key features and benefits of our next-generation Plasma Biomarker Discovery solution. In addition, the case study elaborates on the results from our latest pan-cancer proteomics study.

Case Study – Biognosys Immunopeptidome Profiling Solution for MHC Class I And Class II Neoantigens Discovery in Tumor Biopsies

The case study provides you with an overview of the key features and benefits of our next-generation Immunopeptidome Profiling solution. In addition, the case study elaborates on the results of our latest immunopeptidomics study on lung cancer.

Publication – Dynamic 3D Proteomes Reveal Protein Functional Alterations at High Resolution in Situ

Cappelletti V, Hauser T, Piazza I, Pepelnjak M, Malinovska L, Fuhrer T, Li Y, Dörig C, Boersema P, Gillet L, Grossbach J, Dugourd A, Saez-Rodriguez J, Beyer A, Zamboni N, Caflisch A, Souza N, Picotti P. Cell

In this study, an ETH Zurich team led by Biognosys’ scientific advisor and inventor of the LiP-MS technology, Paola Picotti, has spearheaded the exploration of protein functional states in a proteome-wide manner. The team investigated the role of protein structural alterations as a first-line cellular response. Integrating peptide-level LiP-MS data with orthogonal information such as phosphorylation enabled the linking of protein structural changes to functional implications. This work demonstrates the potential of integrating structural and abundance-based proteomics to achieve deeper insights into biological processes.

Publication – Biomarker Candidates for Tumors Identified from Deep‐Profiled Plasma Stem Predominantly from the Low Abundant Area

Marco Tognetti, Kamil Sklodowski, Sebastian Müller, Dominique Kamber, Jan Muntel, Roland Bruderer and Lukas Reiter.

The plasma proteome has the potential to enable a holistic analysis of the health state of an individual. However, plasma biomarker discovery is difficult due to its high dynamic range and variability. Here, we present a novel automated analytical approach for deep plasma profiling and apply it to a 180-sample cohort of human plasma from lung, breast, colorectal, pancreatic, and prostate cancer.

Publication – Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods

J. Adam Hendricks, Nigel Beaton*, Alexey Chernobrovkin, Eric Miele, Ghaith M. Hamza, Piero Ricchiuto, Ronald C. Tomlinson, Tomas Friman, Cassandra Borenstain, Bernard Barlaam, Sudhir Hande, Michelle L. Lamb, Chris De Savi, Rick Davies, Martin Main, Joakim Hellner, Kristina Beeler, Yuehan Feng, Roland Bruderer, Lukas Reiter, Daniel Martinez Molina*, and M. Paola Castaldi*. American Chemical Society’s Chemical Biology Journal.

The publication shows how orthogonal proteomics approaches can be applied to quantitatively profile the selectivity of a new compound. Biognosys’ proprietary Limited Proteolysis Mass Spectrometry (LiP-MS) technology was used to screen the entire proteome and identify potential targets via structural alterations. In addition to target identification, by exploiting the technology’s peptide-level resolution – a unique feature of the approach – we could also identify the putative binding site of the CDK inhibitor. In this way, LiP-MS enabled the target identification, binding affinity estimation, and binding site localization of the analyzed compound.